TUBB2A as a Candidate Therapeutic Target for Alzheimer's Disease: Orotidine-Mediated Metabolic Mechanisms and Druggability.
Liang Liling L, Zhang Jingjing J, Zhang Ying Y
As the most prevalent neurodegenerative disorder, Alzheimer's disease (AD) poses a pressing need for novel therapeutic targets. This study was designed to address this gap by screening and validating druggable genetic targets nominally associated with AD through an integrative multi-omics approach. Mendelian randomization (MR) screened the druggable genome. GTEx eQTL data and differential expression analysis identified core candidates. SMR, GSMR, and cross-tissue eQTL validation assessed putative causal effects and cross-tissue generalizability. Single-cell RNA sequencing (scRNA-seq) dissected cell type-specific expression. Virtual knockout combined with cell-cell communication analysis elucidated regulatory mechanisms. Mediation analysis evaluated Cerebrospinal fluid (CSF) metabolite involvement, and molecular docking screened therapeutic agents. Genetically predicted TUBB2A expression was nominally associated with AD risk. Virtual knockout analysis revealed that TUBB2A deficiency induced significant upregulation of SLC1A3 and HIF3A, suggesting compensatory glutamate clearance and hypoxic stress responses. Nominal mediation analysis suggested that the CSF metabolite orotidine may be involved in the TUBB2A-AD association. Molecular docking revealed high binding affinity between Eribulin mesylate and TUBB2A. This study identifies TUBB2A as a priority candidate gene for further validation in AD, proposes a potential role for orotidine in TUBB2A-related AD susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies. susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies.